Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
about
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: study design of a randomized controlled trial.Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.Targeted cancer therapies part 1 #276.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.Renal effects of targeted anticancer therapies.Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).Risks associated with sunitinib use and monitoring to improve patient outcomes.Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].
P2860
Q33887946-D31A93A1-F38A-4015-B90F-5F1A779ACAC7Q34974434-BF62D497-887D-4AE0-954F-BD0772AA81A6Q37061324-FAB80E61-8589-48E9-99CB-FBE65388C521Q37584982-23AFD88B-4B6A-452A-B1AD-B97C2153C8F1Q38074121-5E9A5D94-5993-4D2C-9A34-F8616DFD17B9Q38160089-0A3202A3-355B-4F7C-9CBA-33414353CA43Q38367168-BBE360A0-8FCE-4478-B655-707111AC9E96Q38827793-1B39CC37-D8F2-4264-8371-69C9D44CA9CFQ42433181-5086FD5F-165F-447E-B672-3D77B11EA2E4Q48849878-49F30959-86D6-4DE5-AA84-8717A9AF7D98Q54195816-C435216E-2D10-44F3-9492-A5B20F4C8B1F
P2860
Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of adverse events o ...... tastatic renal cell carcinoma.
@en
type
label
Management of adverse events o ...... tastatic renal cell carcinoma.
@en
prefLabel
Management of adverse events o ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P1476
Management of adverse events o ...... tastatic renal cell carcinoma.
@en
P2093
Alvaro Montesa Pino
Begoña Pérez Valderrama
Esther Martínez Ortega
María José Méndez-Vidal
Ruth Viciana
P2860
P2888
P304
P356
10.1007/S10555-012-9355-Y
P478
31 Suppl 1
P577
2012-09-01T00:00:00Z
P6179
1012523961